FOXO4-DRI (FOXO4 D-Retro-Inverso) is an experimental synthetic peptide designed to disrupt the interaction between the FOXO4 and p53 proteins. It is studied as a potential senolytic, a compound intended to target and clear senescent (aged, non-dividing) cells.

What does research suggest about FOXO4-DRI?

Evidence is preclinical only. Some mouse studies have reported senolytic effects, meaning selective targeting of senescent cells and related aging measures. There are no human clinical trials, and animal findings do not reliably translate to people.

Is FOXO4-DRI approved by the FDA?

No. FOXO4-DRI is not an approved medicine anywhere and has not been authorized by the FDA, EMA, or other regulators for any human use. It is classified as an experimental research compound.

Its human safety profile is unknown because no clinical safety studies have been conducted. It is considered highly experimental, and research-market material is also unverified for identity and purity, adding further risk.

What are the side effects of FOXO4-DRI?

The side-effect profile in humans has not been established, since no human studies exist. Potential risks, interactions, and long-term effects remain uncharacterized.

Why is FOXO4-DRI discussed in longevity circles?

The accumulation of senescent cells is a recognized hallmark of aging, and clearing them is a leading research hypothesis. FOXO4-DRI is one experimental senolytic candidate discussed in that context, though its evidence remains limited and preclinical.

Where does the name 'DRI' come from?

DRI stands for D-Retro-Inverso. It refers to a peptide-engineering approach: the amino acid sequence is reversed and built from D-amino acids (the mirror-image form of the usual L-amino acids). The goal is a molecule that keeps a similar 3D shape to the original peptide while resisting the enzymes that would normally break peptides down quickly. It is a design strategy, not a therapeutic claim.

How is FOXO4-DRI different from senolytic drugs like dasatinib or quercetin?

They are grouped under the same broad idea, clearing senescent cells, but they are very different things. Dasatinib is an approved cancer drug and quercetin is a plant flavonoid; both have been studied as a senolytic combination in early human research. FOXO4-DRI is a custom-designed peptide aimed at one specific protein interaction (FOXO4-p53) and, unlike those small molecules, has no completed human trials behind it. Being discussed alongside better-studied compounds does not mean it shares their evidence base.

Why is FOXO4-DRI so widely talked about despite having no human data?

A single high-profile 2017 mouse study produced striking, easy-to-summarize results, and the 'zombie cell' framing is memorable, so the peptide became a popular symbol of anti-aging research online. It is a common misconception to read that attention as clinical validation. Media reach and forum popularity are not the same as human safety or efficacy evidence, which for this compound remains absent.

Where can I buy FOXO4-DRI and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Longevity / Senolytic

Buy FOXO4-DRI – Vendors, Prices, Testing and Evidence

Buy FOXO4-DRI

Also known as: FOXO4 D-Retro-Inverso

Evidence grade D — AnecdotalRisk flag

Short answer

An experimental senolytic peptide discussed in longevity circles. Human evidence is absent.

Where can you buy FOXO4-DRI?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

FOXO4-DRI is a designed peptide intended to disrupt a FOXO4–p53 interaction in senescent cells.

What is not established?

None; preclinical only.

Safety

Highly experimental with unknown human safety; unverified material.

Regulatory status

Not an approved medicine. Experimental research compound.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy FOXO4-DRI: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	FOXO4-DRI research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

FOXO4-DRI research product

Code PEPTIDES10 −10% · discount code details

What is it?

FOXO4-DRI is a designed peptide intended to disrupt a FOXO4–p53 interaction in senescent cells.

Research and evidence

FOXO4-DRI (FOXO4 D-Retro-Inverso) is an experimental, laboratory-designed peptide studied within longevity and senescence research. Its name describes its structure: a D-retro-inverso peptide is a synthetic analogue built from D-amino acids in reversed sequence, an approach used to make a peptide more resistant to breakdown while preserving its interaction shape. FOXO4-DRI was engineered to disrupt the interaction between the FOXO4 protein and the tumor-suppressor protein p53. This interaction is one of the mechanisms that allows senescent cells, aged cells that have stopped dividing but resist dying, to persist in tissue. By interfering with FOXO4-p53 binding, the peptide is proposed to act as a senolytic, nudging these lingering senescent cells toward programmed cell death (apoptosis).

The reason FOXO4-DRI attracts attention is that the accumulation of senescent cells is a recognized hallmark of biological aging, and clearing them is a major hypothesis in the aging-research field. In animal work, some senolytic effects have been reported: mouse studies from the originating research have described selective targeting of senescent cells and associated improvements in certain aging-related measures. It is important to be precise about the strength of this picture, however. The evidence base for FOXO4-DRI is preclinical. There are no human clinical trials establishing that it is effective or safe in people, and results reported in mice do not reliably translate to humans. Much of the discussion around this peptide occurs in longevity and biohacking communities rather than in a body of independently replicated clinical literature.

FOXO4-DRI is not an approved medicine anywhere and is best understood as an experimental research compound. It has not been evaluated or authorized by regulators such as the FDA or EMA for any use in humans, and its human safety profile is genuinely unknown, meaning potential side effects, interactions, and long-term risks have not been characterized. Material sold on research-chemical markets is unverified for identity and purity, adding a further layer of uncertainty. This page is an educational reference summarizing what the current science does and does not show; it is not medical advice, and nothing here should be taken as guidance to obtain or use the compound.

Evidence grade: D

None; preclinical only. Some senolytic effects reported in mouse studies.

Human evidence

None; preclinical only.

Animal and preclinical evidence

Some senolytic effects reported in mouse studies.

Proposed mechanisms

Proposed targeting of senescent cells

Safety concerns and known side effects

Highly experimental with unknown human safety; unverified material.

Unknown profile

Regulatory status

Not an approved medicine. Experimental research compound.

FOXO4-DRI research timeline

2010s
Research into cellular senescence identifies the FOXO4-p53 interaction as a mechanism that keeps senescent ('zombie') cells alive rather than clearing them.
2017
A landmark mouse study (de Keizer group, published in Cell) describes FOXO4-DRI, a designed D-retro-inverso peptide engineered to disrupt FOXO4-p53 binding and selectively push senescent cells into apoptosis; reported effects included improved fitness, fur density and kidney function in aged and treated mice.
late 2010s
The 2017 results drive intense interest in the emerging 'senolytics' field, and FOXO4-DRI becomes a frequently cited proof-of-concept for targeting senescent cells.
early 2020s
Follow-up preclinical and mechanistic work continues in the senolytics area, but no completed human clinical trials of FOXO4-DRI are reported; it remains an experimental research compound with no regulatory approval.
2020s
Despite the absence of human data, unverified FOXO4-DRI material begins circulating in the online 'research chemical' and longevity communities, outpacing the actual state of the evidence.

Frequently asked questions about FOXO4-DRI

What is FOXO4-DRI?: FOXO4-DRI (FOXO4 D-Retro-Inverso) is an experimental synthetic peptide designed to disrupt the interaction between the FOXO4 and p53 proteins. It is studied as a potential senolytic, a compound intended to target and clear senescent (aged, non-dividing) cells.
What does research suggest about FOXO4-DRI?: Evidence is preclinical only. Some mouse studies have reported senolytic effects, meaning selective targeting of senescent cells and related aging measures. There are no human clinical trials, and animal findings do not reliably translate to people.
Is FOXO4-DRI approved by the FDA?: No. FOXO4-DRI is not an approved medicine anywhere and has not been authorized by the FDA, EMA, or other regulators for any human use. It is classified as an experimental research compound.
Is FOXO4-DRI safe?: Its human safety profile is unknown because no clinical safety studies have been conducted. It is considered highly experimental, and research-market material is also unverified for identity and purity, adding further risk.
What are the side effects of FOXO4-DRI?: The side-effect profile in humans has not been established, since no human studies exist. Potential risks, interactions, and long-term effects remain uncharacterized.
Why is FOXO4-DRI discussed in longevity circles?: The accumulation of senescent cells is a recognized hallmark of aging, and clearing them is a leading research hypothesis. FOXO4-DRI is one experimental senolytic candidate discussed in that context, though its evidence remains limited and preclinical.
Where does the name 'DRI' come from?: DRI stands for D-Retro-Inverso. It refers to a peptide-engineering approach: the amino acid sequence is reversed and built from D-amino acids (the mirror-image form of the usual L-amino acids). The goal is a molecule that keeps a similar 3D shape to the original peptide while resisting the enzymes that would normally break peptides down quickly. It is a design strategy, not a therapeutic claim.
How is FOXO4-DRI different from senolytic drugs like dasatinib or quercetin?: They are grouped under the same broad idea, clearing senescent cells, but they are very different things. Dasatinib is an approved cancer drug and quercetin is a plant flavonoid; both have been studied as a senolytic combination in early human research. FOXO4-DRI is a custom-designed peptide aimed at one specific protein interaction (FOXO4-p53) and, unlike those small molecules, has no completed human trials behind it. Being discussed alongside better-studied compounds does not mean it shares their evidence base.
Why is FOXO4-DRI so widely talked about despite having no human data?: A single high-profile 2017 mouse study produced striking, easy-to-summarize results, and the 'zombie cell' framing is memorable, so the peptide became a popular symbol of anti-aging research online. It is a common misconception to read that attention as clinical validation. Media reach and forum popularity are not the same as human safety or efficacy evidence, which for this compound remains absent.
Where can I buy FOXO4-DRI and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

SenolyticsLongevity

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10